M ucosa-associated lymphoid tissue (MALT) lymphoma of the colon is a rare disorder without a standardized treatment approach. Treatment modalities include surgical resection, antibiotic therapy, and chemotherapy.
1,2 MALT lymphoma is defined by the World Health Organization as a subtype of non-Hodgkin lymphoma and classified as an extranodal marginal zone B-cell lymphoma. MALT lymphoma has been diagnosed in different tissues throughout the body, and most commonly the gastrointestinal tract. Gastrointestinal lymphomas constitute 10%-15% of all non-Hodgkin lymphomas. 3 True gastrointestinal lymphoma was clinically defined by Dawson et al 4 in 1961. The lesion must be limited to the gut, without palpable peripheral lymphadenopathy. Nodal involvement must be limited to the lymphatic drainage of the involved gut segment and the peripheral white cell counts should reveal no abnormalities. Surgical cure for MALT has been reported after colonic resection. 5 Systemic therapy used for treatment of colonic MALT includes cyclophosphamide, doxorubicin, vincristine, prednisone; bortezomib; and rituximab-based regimens. [6] [7] [8] There is 1 report of successful monotherapy with rituximab, a monoclonal antibody with activity against CD20-positive cell types. 9 The aim of this study was to review our experience with primary colonic MALT lymphoma.
Methods
Institutional review board approval was obtained to review an institutional database of 3461 patients with diagnostic and treatment data for patients diagnosed with non-Hodgkin lymphoma from January 2000 through September 2015. All patients with MALT lymphoma of the colon were included. Exclusion criteria were patients with extracolonic disease, other known gastrointestinal disease, and those who underwent surgical resection for diagnosis. A total of 208 patients were identified with a diagnosis of MALT, whereas only 7 patients had gastrointestinal involvement limited to the colon. Three patients were excluded from the dataset because of extensive hematologic disease burden, lack of treatment data, and 1 patient underwent surgical resection for recurrent lower gastrointestinal bleed.
Immunohistochemistry
Paraffin section immunohistochemistry was performed with appropriate positive and negative controls. Fluorescent in situ hybridization (FISH) for a translocation involving the MALT1 gene (18q21) was performed. The dual color, break-apart probe consisting of a mixture of 2 FISH DNA probes on chromosome 18 (Abbott Molecular, Des Plaines, IL) was used in this interphase FISH assay to detect the presence of the 18q21 locus. FISH was also performed for a translocation involving the BCL gene (18q21). The dual color, breakapart probe flanking the centromeric and telomeric sides of the BCL2 locus (Abbott Molecular) was used to evaluate for the presence or absence of a translocation involving the BCL2 gene.
B-cell clonality determination
DNA was isolated from the formalin-fixed, paraffinembedded specimen and subjected to polymerase chain reaction amplification using fluorescently labeled primers targeting the immunoglobulin heavy chain and immunoglobulin light chain kappa loci (InVivoScribes, San Diego, CA). Fluorescently labeled polymerase chain reaction products were analyzed by capillary gel electrophoresis.
Results
Four patients underwent routine colonoscopy for screening or surveillance that resulted in a diagnosis of MALT lymphoma in the colon without nodal disease (Table 1) . In all cases, the neoplastic lymphocytes were strongly and diffusely positive for CD20. A total of 3 out of 4 cases were strongly and diffusely positive for BCL-2. The neoplastic lymphocytes were negative for T-cell markers, CD10, cyclin D1, and BCL-6. FISH for MALT1 was done in 3 cases, 2 of which were positive. FISH for BCL2 was performed on 1 case lacking MALT1 translocation and it was negative.
One patient had a mild anemia, but otherwise all were in their usual state of health without symptoms related to colonic MALT at the time of diagnosis. All patients were clinically staged before endoscopic resection followed by intravenous rituximab, eventually leading to remission in all 4 patients. Two patients had disease at early surveillance colonoscopy at 4 and 10 months, both in different areas of the colon than the original lymphoma. Three patients received treatment with weekly infusion of 375 mg/m 2 intravenous rituximab for a duration of 4 weeks, whereas 1 continued on maintenance rituximab for treatment of a concurrent follicular lymphoma. The average disease-free survival was 57 months, with average length of follow-up of 51 months after completion of rituximab therapy.
Discussion
To date, a treatment approach has not been standardized for primary colonic MALT because of the indolent nature and rarity of this condition. The recurrence is not always in the original area of disease, so primary resection may not prevent recurrence. Our experience provides support that early colonic MALT lymphoma may be safely treated by nonoperative management, avoiding the morbidity that is associated with surgical resection. Endoscopic resection followed by rituximab seems to be a valid treatment option for this entity with a reasonably good disease-free survival. 
